June is Alzheimer’s and Brain Awareness Month – it is a global healthcare event that highlights the importance of early diagnosis and shows support for the millions of people worldwide living with Alzheimer’s or another form of dementia.

Alzheimer’s is a neurodegenerative disorder that affects people over the age of 65 and impacts cognitive processes. Although memory loss is the earliest symptom of Alzheimer’s, other issues such as behavioral changes, difficulty in communicating, not being aware of surroundings or recent experiences, and mood changes can emerge as the disease progresses, resulting in self-isolation from friends and family.

Nearly 50 million people are currently living with dementia worldwide. More alarmingly, that number is expected to reach 132 million by 2050.

It is a good idea to consult with a healthcare professional when memory lapses become frequent enough or sufficiently noticeable to concern you or a family member. Early diagnosis can treat reversible causes of memory loss, or improve the quality of life in Alzheimer’s or other types of dementia.

GCT is proud to be taking an active part in the research and drug development for Alzheimer’s disease. Please contact us at bd@gctrials.com to find out more about our CNS portfolio and how we can assist you in conducting a clinical trial.